[Studies on coronary-active substances].
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001775:Blood Circulation / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002463:Cell Membrane Permeability; D003286:Contracture; D003327:Coronary Disease / Q000188:drug therapy*; D004285:Dogs; D004558:Electric Stimulation; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy; D007474:Ion Exchange; D009206:Myocardium / Q000378:metabolism; D009570:Nitriles / Q000627:therapeutic use*; D010208:Papaverine / Q000494:pharmacology; D011188:Potassium / Q000378:metabolism; D011299:Prenylamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D009570:Nitriles; D014665:Vasodilator Agents; D011433:Propranolol; D014700:Verapamil; D010208:Papaverine; D011299:Prenylamine; D011188:Potassium; D002118:Calcium
Studien mit coronariwrksamen Substanzen.